Keith Knutson

Professor, Immunology Mayo Clinic

Keith L. Knutson, Ph.D. is the Andrew A. and Mary S. Sugg Professor of Cancer Research and Professor of Immunology at Mayo Clinic in Florida, with a joint appointment in Cancer Biology. He serves as Director of the Mayo Clinic Florida Cell Analysis and Cell Imaging Core, Co-Director of the Mayo Clinic Comprehensive Cancer Center Cancer Immunology and Immunotherapy Program, and Vice Chair of the Mayo Clinic Enterprise Research Personnel Committee.

Dr. Knutson received his B.S. in Microbiology from the University of Washington, his Ph.D. in Physiology and Pharmacology from the University of Georgia and completed postdoctoral training in immunology at the University of British Columbia and the University of Washington.

An internationally recognized leader in cancer immunology, Dr. Knutson has authored more than 195 peer-reviewed publications. His research focuses on the development and clinical translation of immunotherapies for breast, ovarian, and lung cancers, with particular emphasis on therapeutic and preventive cancer vaccines. He has led numerous early-phase clinical trials and currently serves as principal investigator on multiple NIH- and Department of Defense-funded projects.

Dr. Knutson is an active mentor, frequent invited speaker, and reviewer for NIH and DOD study sections. His honors include the NIH Howard Temin Award, the AACR Young Investigator Award, Mayo Clinic Florida Investigator of the Year, and election as a two-time Susan G. Komen Scholar.

Seminars

Wednesday 2nd December 2026
Chair’s Opening Remarks
8:50 am
Wednesday 2nd December 2026
Benchmarking Dendritic Cells Against Other Vaccine Platforms to Reveal Advantages & Overcoming Challenges, Helping Advance Effective Cancer Vaccines
12:00 pm
  • Evaluating dendritic cell vaccine platforms against RNA, peptide and viral vector based approaches to select the most clinically relevant approach
  • Highlighting molecular and cellular features of effective dendritic cell vaccines, including overcoming challenges with abnormal differentiation
  • Uncovering strategies for preventing cancer recurrence and improving treatments for the patients in need
Wednesday 2nd December 2026
Chair’s Closing Remarks
5:00 pm
Keith Knutson